Ultragenyx stake: AQR reports 6.66% ownership
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report passive ownership of Ultragenyx Pharmaceutical Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report passive ownership of Ultragenyx Pharmaceutical Inc. common stock. They beneficially own 6,560,809 shares, representing 6.66% of Ultragenyx’s common stock.
The AQR entities report shared voting power over 6,398,809 shares and shared dispositive power over 6,560,809 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule is filed on behalf of both entities.
Key Figures
Key Terms
beneficially owned financial
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Ultragenyx (RARE) does AQR Capital report owning?
Which AQR entities are reporting ownership in Ultragenyx (RARE)?
AI-generated analysis. How Rhea-AI works. Not financial advice.